Companies: 10,795·Total market cap: $144.5T

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

FDMTNASDAQHealthcare● Active

$8.64

$-1.37(-13.69%)

Market Cap$451666835

P/E Ratio—

52W High$12.34

52W Low$3.68

Avg Volume744K

Open$9.93

Beta2.76

Net Income Financials Revenue

4D Molecular Therapeutics, Inc. (FDMT) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

FDMT · net income · updated Jun 8, 2026

Core profitability metrics

FDMT · net income · margin · TTM · CAGR

Net income was −$140.1M for FY2025 (fiscal year ending 2025-12-31), up 12.9% year-over-year. Net profit margin was -164.4%.

FY2025 Net Income−$140.1M▲ +12.9% YoY

Trailing 12M (TTM)−$160.9Mtrailing 4 quarters sum

Net Profit Margin-164.4%−$140.1M ÷ $85.2M

YoY Change+12.9%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · FDMT net income history · FDMT profit margin

Annual net income data

FDMT · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$140.1M▲ +12.9%-164.4%$85.2M

FY2024Loss−$160.9M▼ 59.5%-434778.4%$37,000

FY2023Loss−$100.8M▲ +6.2%-486.6%$20.7M

FY2022Loss−$107.5M▼ 50.7%-3435.4%$3.1M

FY2021Loss−$71.3M▼ 25.8%-395.4%$18.0M

Net income vs peers (Healthcare)

FDMT vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

4D Molecular Therapeutics, Inc.YOU

FDMT

−$140.1M+12.9%-164.4%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

4D Molecular Therapeutics, Inc. (FDMT) reported net income of −$140.1M for FY2025 (fiscal year ending 2025-12-31), up 12.9% year-over-year. The net profit margin was -164.4% — meaning the company kept $-1.64 of every dollar of revenue as profit.

4D Molecular Therapeutics, Inc. has not yet achieved annual profitability based on available data (9 fiscal years). The company has reported net losses across all available periods.

4D Molecular Therapeutics, Inc.'s net profit margin was -164.4% for FY2025, based on the latest annual results.

Investors sometimes search for "4D Molecular Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from FDMT net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

FDMT net income · 4 questions

4D Molecular Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $140.1M for FY2025.

is FDMT profitabledoes FDMT make a profitFDMT profitabilityFDMT profitable company

▸ Source: FMP /income-statement · GAAP · 4D Molecular Therapeutics, Inc. · 4D Molecular Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026